TriangleVenetoclax (NCT03214562)
Venetoclax trial for Acute Myeloid Leukemia (NCT03214562). This is a short film with English narration. The transcript is on this page, and the written brief is separate.
What the film says
Read the transcript
This trial is for acute myeloid leukemia, newly diagnosed or one that has come back.
The idea: add a targeted pill to standard intensive chemotherapy. The pill, venetoclax, blocks a protein called BCL-2. It is taken by mouth for part of each cycle, alongside a chemotherapy regimen called FLAG-IDA.
In a published report of 138 patients, 95 percent of newly diagnosed patients reached remission. Infections and low blood counts were common. It was a single group, with no comparison. At MD Anderson in Houston, Courtney DiNardo leads the study.
Public record; not medical advice.
Already in a trial?
It turns into a project to manage: visits, scans, labs, side effects and paperwork. Triangle keeps it organized in one place for you or for whoever's helping.
Organize my trial7-day free trial, then $9 a month. Cancel anytime.
How these trials work: what Phase 1 actually is · common questions Not clinical evidence.